Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Hepatitis C virus infection and spontaneous clearance in HTLV-1 and HIV co-infected patients in Salvador, Bahia, Brazil.

Le Marchand C, Bahia F, Page K, Brites C.

Braz J Infect Dis. 2015 Sep-Oct;19(5):486-91. doi: 10.1016/j.bjid.2015.06.007. Epub 2015 Aug 5.

2.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

3.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

4.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

5.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

6.

Improvement of the methods for skin mechanical properties evaluation through correlation between different techniques and factor analysis.

Neto P, Ferreira M, Bahia F, Costa P.

Skin Res Technol. 2013 Nov;19(4):405-16. doi: 10.1111/srt.12060. Epub 2013 May 1.

PMID:
23635400
7.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

8.

Platelet count kinetics following interruption of antiretroviral treatment.

Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group.

AIDS. 2013 Jan 2;27(1):59-68. doi: 10.1097/QAD.0b013e32835a104d.

9.

The impact of human T-cell lymphotropic virus I infection on clinical and immunologic outcomes in patients coinfected with HIV and hepatitis C virus.

Bahia F, Novais V, Evans J, Le Marchand C, Netto E, Page K, Brites C.

J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 3:S202-7. doi: 10.1097/QAI.0b013e31821e9a1e.

10.

Efficacy of anti-wrinkle products in skin surface appearance: a comparative study using non-invasive methods.

Pena Ferreira MR, Costa PC, Bahia FM.

Skin Res Technol. 2010 Nov;16(4):444-9. doi: 10.1111/j.1600-0846.2010.00458.x.

PMID:
20923458
11.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

12.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

13.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

14.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.

PMID:
18765698
15.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

16.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

17.

Evaluation of the genotypic pattern of HIV-1 resistance in AIDS patients failing antiretroviral therapy.

Bahia F, Pedroso C, Netto EM, Figueiredo R, Pinto Neto L, Brites C.

Braz J Infect Dis. 2004 Aug;8(4):281-9. Epub 2004 Nov 19.

18.

A randomized, pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients allergic to sulfonamides.

Straatmann A, Bahia F, Pedral-Sampaio D, Brites C.

Braz J Infect Dis. 2002 Dec;6(6):276-80. Epub 2003 Nov 3.

20.

Evaluation of carboxymethylcellulose, hydroxypropylmethylcellulose, and aluminum hydroxide as potential carriers for rhBMP-2.

Santa-Comba A, Pereira A, Lemos R, Santos D, Amarante J, Pinto M, Tavares P, Bahia F.

J Biomed Mater Res. 2001 Jun 5;55(3):396-400.

PMID:
11255193
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk